Paint Therapeutics LLC
Develops tissue-targeted drug delivery technology based on endogenous surfactant peptide motifs to increase local retention and controlled release of therapeutics in specific tissues (lung, brain/CNS, GI). Operates a modular discovery platform to identify targeting motifs and advances drug candidates through discovery, preclinical and IND-enabling stages.
Industries
N/A
Nr. of Employees
small (1-50)
Paint Therapeutics LLC
Contact form on site and media contact information listed on media center
Products
Lung-targeted delivery formulations
Formulations designed to deliver and retain therapeutics in pulmonary tissue to provide prolonged local activity.
Brain/CNS-targeted delivery formulations
Formulations designed to cross or work with the blood–brain barrier to deliver and retain therapeutics in CNS tissues.
Gastrointestinal tract-targeted delivery formulations
Formulations aimed at reducing rapid transit and enzymatic breakdown to retain therapeutics in the GI tract.
Lung-targeted delivery formulations
Formulations designed to deliver and retain therapeutics in pulmonary tissue to provide prolonged local activity.
Brain/CNS-targeted delivery formulations
Formulations designed to cross or work with the blood–brain barrier to deliver and retain therapeutics in CNS tissues.
Gastrointestinal tract-targeted delivery formulations
Formulations aimed at reducing rapid transit and enzymatic breakdown to retain therapeutics in the GI tract.
Services
Internal modular platform to identify peptide-based motifs that target and retain therapeutics in specific tissues.
Internal modular platform to identify peptide-based motifs that target and retain therapeutics in specific tissues.
Expertise Areas
- Tissue-targeted drug delivery
- Formulation for controlled, local release
- Preclinical development and IND-enabling
- Discovery of tissue-targeting motifs
Key Technologies
- Surfactant peptide-based delivery carriers
- Tissue-specific targeting motifs
- Controlled-release formulations
- siRNA delivery
News & Updates
Site news entry indicating forthcoming company news.
Media center article posted on the company's site (example news item).
Post describing a strategic partnership by a third party (SirnaMed) to develop RNA-based therapeutics for emerging viral threats; published on site.
Site news entry indicating forthcoming company news.
Media center article posted on the company's site (example news item).
Post describing a strategic partnership by a third party (SirnaMed) to develop RNA-based therapeutics for emerging viral threats; published on site.